ArticleInternational urology and nephrology2026
Association of ERAS protocol adherence with complications and readmissions following open radical cystectomy: a pilot study from an ERAS Society-qualified centre.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis pilot study evaluated the association between Enhanced Recovery After Surgery (ERAS) protocol adherence and postoperative outcomes following open radical cystectomy (RC), with a focus on complications and readmissions.
methodsThe ERAS® RC pathway (20 strongly recommended items) was implemented at our ERAS®-qualified center (AO Santa Croce e Carle) from October 2019. Prospective perioperative data were collected for the first 100 consecutive patients. No non-ERAS or historical control group was included. The outcomes included in-hospital and 30-day complications, readmissions within 30 days, and readmissions occurring between postoperative days 31 and 90. Postoperative ERAS adherence ≥70% was defined as good postoperative compliance. Logistic regression assessed associations between adherence and outcomes. The primary endpoint was the association between ERAS adherence and early complications; the secondary endpoint was readmission occurring between postoperative days 31 and 90 and its potential predictors.
resultsMost patients were male (88%), with a mean age of 72.2 ± 7.9 years; 95% underwent RC for oncologic indications. Mean length of stay (LOS) was 10.5 ± 7.1 days. Within 30 days, 65% experienced complications, predominantly Clavien-Dindo grade II; urinary tract infections were the most frequent (40%). Seventeen patients (17%) were readmitted within 30 days and 12 patients (12%) experienced at least one readmission between postoperative days 31 and 90. Because seven patients were readmitted during both intervals, the cumulative 90-day readmission rate was 22%. ERAS adherence was high preoperatively (95.5%) and intraoperatively (99.2%), but lower postoperatively (65.8%). Adherence ≥70% was significantly associated with shorter LOS (p=0.001) and fewer 30-day complications (p=0.012). In multivariable models, higher postoperative ERAS adherence remained independently associated with lower odds of in-hospital (p=0.0004) and 30-day complications (p=0.001). No significant association was observed between the ≥70% adherence threshold and readmissions occurring between postoperative days 31 and 90.
conclusionsHigher postoperative ERAS adherence was independently associated with fewer early complications and a shorter length of stay among patients undergoing open radical cystectomy within an established ERAS pathway. These findings support the clinical relevance of structured ERAS delivery with continuous adherence monitoring and warrant multicenter validation across both open and minimally invasive approaches.
Indexed as
Identifiers
42661038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.